NABP to Develop National Adverse Event Reporting Clearinghouse for Compounded Medications
核心洞察
The National Association of Boards of Pharmacy announced a new initiative to build a national adverse event reporting clearinghouse for compounded medications, closing a longstanding gap in patient-safety tracking infrastructure.
Compounded preparations from 503A pharmacies currently fall outside the FDA-mandated federal adverse event reporting system, leaving no central mechanism for state boards and the FDA to share harm reports.
The surge in compounded GLP-1 (搜索) medications and evolving business models has pushed compounding beyond the small-scale, patient-specific model the current regulatory framework was designed to support.
The National Association of Boards of Pharmacy (NABP (搜索)) announced on July 29, 2026, a new initiative to develop a national adverse event reporting clearinghouse for compounded medications. The system, unveiled from the Association's headquarters in Mount Prospect, Illinois, will capture reports of patient harm and share that information among state boards of pharmacy and with the US Food and Drug Administration (FDA), directly addressing what NABP describes as a longstanding gap in the federal adverse event reporting infrastructure.
The initiative responds to a structural vulnerability in the current regulatory framework: compounded preparations dispensed by 503A pharmacies fall outside the federal adverse event reporting system mandated by the FDA for registered drug manufacturers and 503B outsourcing facilities. When a patient is harmed by a compounded medication from a dispensing pharmacy, no federal requirement ensures that the event is recorded. Even when an event is voluntarily recorded, no central system exists that allows state boards and the FDA to view the adverse report.
"When a patient is harmed by a compounded medication, that information too often stays in one state, or never surfaces at all," said Lemrey "Al" Carter, PharmD, MS, RPh, executive director of NABP (搜索). "We cannot protect patients from risks regulators cannot see. A national clearinghouse would let the boards of pharmacy and FDA share what each of them learns, so that a harm detected in one state can protect patients in every other state. This is the type of project that NABP is uniquely positioned to conduct and, working with our member boards and the FDA, we intend to champion it."
Regulatory Gaps Exposed by Compounding Surge
NABP (搜索) detailed the reporting gap in its formal comment to the FDA Pharmacy Compounding Advisory Committee (PCAC), which recently convened to review seven peptide substances proposed for compounding under Section 503A. In those comments, NABP described how the recent surge in compounded GLP-1 (搜索) medications and evolving business models has pushed compounding far past the small-scale, patient-specific model the current regulatory framework was built to support.
The Association identified several additional structural gaps that grow more consequential as compounding volume increases: limits on the information that federal and state regulators can share with one another, the absence of supply-chain traceability tools for compounded products, and the difficulty of verifying the bulk substances from which compounded medications are made.
Coordinated Patient-Safety Measures
The adverse event reporting clearinghouse represents the first and most direct response to these gaps and is designed to strengthen the flow of safety information. Beyond the clearinghouse, NABP (搜索) and its member boards intend to pursue a coordinated set of patient-safety measures, including working with the FDA to expand real-time information sharing within existing legal authority, developing model standards for verifying bulk drug substances used in compounding, and building coordinated referral pathways among boards of pharmacy, state medical boards, and state attorneys general for cases that cross jurisdictional lines.
In the coming months, the Association will convene boards of pharmacy, FDA, and other industry stakeholders to define the clearinghouse design, governance, and connection to state and federal reporting programs.